Follow
Peter Iversen
Peter Iversen
Professor of Urology, Copenhagen Prostate Cancer Center, Rigshospitalet. Department of Clinical
Verified email at rh.regionh.dk
Title
Cited by
Cited by
Year
Enzalutamide in metastatic prostate cancer before chemotherapy
TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
New England Journal of Medicine 371 (5), 424-433, 2014
32972014
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
FR Schumacher, AA Al Olama, SI Berndt, S Benlloch, M Ahmed, ...
Nature genetics 50 (7), 928-936, 2018
7602018
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
Prostate Cancer Trialists Collaborative Group
The Lancet 355 (9214), 1491-1498, 2000
5402000
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer
AA Al Olama, Z Kote-Jarai, SI Berndt, DV Conti, F Schumacher, Y Han, ...
Nature genetics 46 (10), 1103-1109, 2014
5202014
Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup
P Iversen, CJ Tyrrell, AV Kaisary, JB ANDERSON, H Van Poppel, ...
The Journal of urology 164 (5), 1579-1582, 2000
5042000
Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study
TM Beer, AJ Armstrong, D Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
European urology 71 (2), 151-154, 2017
4362017
A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate …
CJ Tyrrell, AV Kaisary, P Iversen, JB Anderson, L Baert, T Tammela, ...
European urology 33 (5), 447-456, 1998
4191998
Climate instability during the last interglacial period recorded in the GRIP ice core
Greenland Ice-core Project (GRIP) Members
Nature 364 (6434), 203-207, 1993
3991993
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
DG McLEOD, P Iversen, WA See, T Morris, JON Armstrong, MP Wirth, ...
BJU international 97 (2), 247-254, 2006
3842006
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
DV Conti, BF Darst, LC Moss, EJ Saunders, X Sheng, A Chou, ...
Nature genetics 53 (1), 65-75, 2021
2972021
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early …
WA See, MP Wirth, DG McLeod, P Iversen, I Klimberg, D Gleason, ...
The Journal of urology 168 (2), 429-435, 2002
2842002
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early …
WA See, MP Wirth, DG McLeod, P Iversen, I Klimberg, D Gleason, ...
The Journal of urology 168 (2), 429-435, 2002
2822002
A point system for selecting operative candidates
PO Madsen, P Iversen
Benign prostatic hypertrophy, 763-765, 1983
2801983
Active surveillance for clinically localized prostate cancer––A systematic review
FB Thomsen, K Brasso, LH Klotz, MA Røder, KD Berg, P Iversen
Journal of surgical oncology 109 (8), 830-835, 2014
2392014
Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer …
MP Wirth, WA See, DG McLEOD, P Iversen, T Morris, K Carroll, ...
The Journal of urology 172 (5), 1865-1870, 2004
2392004
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized …
P Iversen, CJ Tyrrell, AV Kaisary, JB Anderson, L Baert, T Tammela, ...
Urology 51 (3), 389-396, 1998
2201998
Value of postvoid residual urine determination in evaluation of prostatism
RC Bruskewitz, P Iversen, PO Madsen
Urology 20 (6), 602-604, 1982
1951982
Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts
TM Seibert, CC Fan, Y Wang, V Zuber, R Karunamuni, JK Parsons, ...
bmj 360, 2018
1762018
Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer
ML Huber, L Haynes, C Parker, P Iversen
Journal of the National Cancer Institute 104 (4), 273-279, 2012
1722012
Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer
ML Huber, L Haynes, C Parker, P Iversen
Journal of the National Cancer Institute 104 (4), 273-279, 2012
1722012
The system can't perform the operation now. Try again later.
Articles 1–20